These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21509710)

  • 1. Evaluation of desmopressin effect on primary haemostasis in pediatric patients with aspirin-like defect as hereditary thrombocytopathy.
    Tauer JT; Gneuss A; Lohse JE; Jürgens T; Knöfler R
    Klin Padiatr; 2011 May; 223(3):169-72. PubMed ID: 21509710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
    Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
    Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin.
    Trummer A; Haarmeijer B; Werwitzke S; Wermes C; Ganser A; Budde U; Tiede A
    Haemophilia; 2013 Mar; 19(2):236-41. PubMed ID: 23051555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Desmopressin parenteral in patients with VWD1, VWD 2A and thrombocytopathy].
    Siegmund B; Pollmann H
    Hamostaseologie; 2011 Nov; 31 Suppl 1():S29-33. PubMed ID: 22057258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
    Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
    Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis.
    Arshad F; Stoof SC; Leebeek FW; Ruitenbeek K; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Kruip MJ; Lisman T
    Liver Int; 2015 Jul; 35(7):1809-15. PubMed ID: 25522671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome.
    Pfueller SL; Howard MA; White JG; Menon C; Berry EW
    Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aspirin-like defect - a hereditary thrombocytopathy due to impaired release of platelet adenosine diphosphate].
    Elezović I; Mijović A; Rolović Z
    Bilt Hematol Transfuz; 1979; 7(2-3):165-74. PubMed ID: 263623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
    Favaloro EJ
    Semin Thromb Hemost; 2006 Sep; 32(6):566-76. PubMed ID: 16977567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.
    Favaloro EJ; Kershaw G; Bukuya M; Hertzberg M; Koutts J
    Haemophilia; 2001 Mar; 7(2):180-9. PubMed ID: 11260278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.